{"id":"trimethoprim","rwe":[],"_fda":{"id":"b44a332e-98a1-4f1b-b06b-3a9b044cb926","set_id":"079c828c-148f-45b9-966e-d8906043b2a2","openfda":{"nui":["N0000175504","M0020790","N0000185504","N0000175489","N0000000191","N0000187062","N0000187061"],"unii":["JE42381TNV","AN164J8Y0X"],"route":["ORAL"],"rxcui":["198335"],"spl_id":["b44a332e-98a1-4f1b-b06b-3a9b044cb926"],"brand_name":["Sulfamethoxazole and Trimethoprim"],"spl_set_id":["079c828c-148f-45b9-966e-d8906043b2a2"],"package_ndc":["55700-611-06","55700-611-10","55700-611-14","55700-611-20","55700-611-28","55700-611-30"],"product_ndc":["55700-611"],"generic_name":["SULFAMETHOXAZOLE AND TRIMETHOPRIM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Sulfonamides [CS]"],"substance_name":["SULFAMETHOXAZOLE","TRIMETHOPRIM"],"pharm_class_epc":["Sulfonamide Antimicrobial [EPC]","Dihydrofolate Reductase Inhibitor Antibacterial [EPC]"],"pharm_class_moa":["Cytochrome P450 2C9 Inhibitors [MoA]","Dihydrofolate Reductase Inhibitors [MoA]","Cytochrome P450 2C8 Inhibitors [MoA]","Organic Cation Transporter 2 Inhibitors [MoA]"],"manufacturer_name":["Quality Care Products LLC"],"application_number":["ANDA090624"],"original_packager_product_ndc":["57237-233"]},"version":"12","warnings":["WARNINGS Embryofetal Toxicity Some epidemiologic studies suggest that exposure to sulfamethoxazole and trimethoprim during pregnancy may be associated with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular malformations, urinary tract defects, oral clefts, and club foot. If sulfamethoxazole and trimethoprim is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential hazards to the fetus. Hypersensitivity and Other Fatal Reactions Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sulfonamides, including sulfonamide-containing products such as sulfamethoxazole and trimethoprim, should be discontinued at the first appearance of skin rash or any sign of adverse reaction. In rare instances, a skin rash may be followed by a more severe reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, and serious blood disorders (see PRECAUTIONS ). Clinical signs, such as rash, sore throat, fever, arthralgia, pallor, purpura or jaundice may be early indications of serious reactions. Cough, shortness of breath, and pulmonary infiltrates are hypersensitivity reactions of the respiratory tract that have been reported in association with sulfonamide treatment. Thrombocytopenia Sulfamethoxazole and trimethoprim-induced thrombocytopenia may be an immune-mediated disorder. Severe cases of thrombocytopenia that are fatal or life threatening have been reported. Thrombocytopenia usually resolves within a week upon discontinuation of sulfamethoxazole and trimethoprim. Streptococcal Infections and Rheumatic Fever The sulfonamides should not be used for treatment of group A β-hemolytic streptococcal infections. In an established infection, they will not eradicate the streptococcus and, therefore, will not prevent sequelae such as rheumatic fever. Clostridium Difficile Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including sulfamethoxazole and trimethoprim, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Adjunctive Treatment with Leucovorin for Pneumocystis jiroveci Pneumonia Treatment failure and excess mortality were observed when trimethoprim-sulfamethoxazole was used concomitantly with leucovorin for the treatment of HIV positive patients with Pneumocystis jiroveci pneumonia in a randomized placebo controlled trial. 6 Co-administration of trimethoprim-sulfamethoxazole and leucovorin during treatment of Pneumocystis jiroveci pneumonia should be avoided."],"pregnancy":["Pregnancy While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell, 10 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter. Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenic Effects Pregnancy Category D Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic studies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple statistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures varied between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim exposure and specific malformations. Animal Data In rats, oral doses of either 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates. These doses are approximately 5 and 6 times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss (dead and resorbed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section."],"overdosage":["OVERDOSAGE Acute The amount of a single dose of sulfamethoxazole and trimethoprim that is either associated with symptoms of overdosage or is likely to be life-threatening has not been reported. Signs and symptoms of overdosage reported with sulfonamides include anorexia, colic, nausea, vomiting, dizziness, headache, drowsiness and unconsciousness. Pyrexia, hematuria and crystalluria may be noted. Blood dyscrasias and jaundice are potential late manifestations of overdosage. Signs of acute overdosage with trimethoprim include nausea, vomiting, dizziness, headache, mental depression, confusion and bone marrow depression. General principles of treatment include the institution of gastric lavage or emesis, forcing oral fluids, and the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant blood dyscrasia or jaundice occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating sulfamethoxazole and trimethoprim. Chronic Use of sulfamethoxazole and trimethoprim at high doses and/or for extended periods of time may cause bone marrow depression manifested as thrombocytopenia, leukopenia and/or megaloblastic anemia. If signs of bone marrow depression occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored."],"references":["REFERENCES Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. J Clin Pharmacol . Feb-Mar 1974; 14:112–117. Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man. J Infect Dis . Nov 1973; 128 (Suppl): S547–S555. Varoquaux O, et al. Pharmacokinetics of the trimethoprim-sulfamethoxazole combination in the elderly. Br J Clin Pharmacol . 1985;20:575–581. Rudoy RC, Nelson JD, Haltalin KC. Antimicrobial Agents Chemother . May 1974;5:439–443. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 9 th ed. CLSI document M07– A9, CLSI, Wayne, PA, 2012. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis . 1994 Oct;170(4):912-7. Hardy DW, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med . 1992; 327: 1842–1848. Marinella Mark A. 1999. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontol . 45:209–212. Margassery, S. and B. Bastani. 2002. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. J. Nephrol . 14:410–414. Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of Bacteriuria in Women. J Infect Dis . Nov 1973; 128 (Suppl):S657–S663. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med . 1992; 327: 1853–1880. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR. 1992; 41(RR-4):1–11. CDC Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR . 1991; 40(RR-2):1–13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard – 11 th ed . CLSI document M02–A11, CLSI, Wayne, PA, 2012. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement , CLSI document M100–S23. CLSI document M100–S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013. Distributed by: Rising Health, LLC Saddle Brook, NJ 07663 Made in India Code: TS/DRUGS/22/2009 Revised: 12/2017"],"description":["DESCRIPTION Sulfamethoxazole and trimethoprim is a synthetic antibacterial combination product available in DS (double strength) tablets, each containing 800 mg sulfamethoxazole and 160 mg trimethoprim; in tablets, each containing 400 mg sulfamethoxazole and 80 mg trimethoprim for oral administration. Sulfamethoxazole is N 1 -(5-methyl-3-isoxazolyl)sulfanilamide; the molecular formula is C 10 H 11 N 3 O 3 S. It is a white to off-white, practically odorless, crystalline powder, tasteless compound with a molecular weight of 253.28 and the following structural formula: Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine; the molecular formula is C 14 H 18 N 4 O 3 . It is a white or cream-colored crystals or crystalline powder with a molecular weight of 290.3 and the following structural formula: Inactive Ingredients: Docusate sodium, magnesium stearate, pregelatinized starch (maize), sodium benzoate, and sodium starch glycolate. Sulfamethoxazole Chemical Structure Trimethoprim Chemical Structure"],"precautions":["PRECAUTIONS Development of Drug Resistant Bacteria Prescribing sulfamethoxazole and trimethoprim tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Folate Deficiency Sulfamethoxazole and trimethoprim should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with malabsorption syndrome, and patients in malnutrition states) and to those with severe allergies or bronchial asthma. Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure. These effects are reversible by folinic acid therapy. Hemolysis In glucose-6-phosphate dehydrogenase deficient individuals, hemolysis may occur. This reaction is frequently dose-related (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ). Hypoglycemia Cases of hypoglycemia in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk. Phenylalanine Metabolism Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction. Porphyria and Hypothyroidism As with all drugs containing sulfonamides, caution is advisable in patients with porphyria or thyroid dysfunction. Use in the Treatment of and Prophylaxis for Pneumocystis jiroveci Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS) AIDS patients may not tolerate or respond to sulfamethoxazole and trimethoprim in the same manner as non-AIDS patients. The incidence of side effects, particularly rash, fever, leukopenia and elevated aminotransferase (transaminase) values, with sulfamethoxazole and trimethoprim therapy in AIDS patients who are being treated for P. jiroveci pneumonia has been reported to be greatly increased compared with the incidence normally associated with the use of sulfamethoxazole and trimethoprim in non-AIDS patients. Adverse effects are generally less severe in patients receiving sulfamethoxazole and trimethoprim for prophylaxis. A history of mild intolerance to sulfamethoxazole and trimethoprim in AIDS patients does not appear to predict intolerance of subsequent secondary prophylaxis. 7 However, if a patient develops skin rash or any sign of adverse reaction, therapy with sulfamethoxazole and trimethoprim should be reevaluated (see WARNINGS ). Co-administration of sulfamethoxazole and trimethoprim and leucovorin should be avoided with P. jiroveci pneumonia (see WARNINGS ). Electrolyte Abnormalities High dosage of trimethoprim, as used in patients with P. jiroveci pneumonia, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause hyperkalemia when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or if drugs known to induce hyperkalemia are given concomitantly. Close monitoring of serum potassium is warranted in these patients. Severe and symptomatic hyponatremia can occur in patients receiving sulfamethoxazole and trimethoprim, particularly for the treatment of P. jiroveci pneumonia. Evaluation for hyponatremia and appropriate correction is necessary in symptomatic patients to prevent life-threatening complications. During treatment, adequate fluid intake and urinary output should be ensured to prevent crystalluria. Patients who are “slow acetylators” may be more prone to idiosyncratic reactions to sulfonamides. Information for Patients Patients should be counseled that antibacterial drugs including sulfamethoxazole and trimethoprim tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When sulfamethoxazole and trimethoprim tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance, and will not be treatable by sulfamethoxazole and trimethoprim tablets or other antibacterial drugs in the future. Patients should be instructed to maintain an adequate fluid intake in order to prevent crystalluria and stone formation. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Laboratory Tests Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, sulfamethoxazole and trimethoprim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with impaired renal function. Drug Interactions Potential for Sulfamethoxazole and Trimethoprim to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Caution is recommended when sulfamethoxazole and trimethoprim is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2. In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. It has been reported that sulfamethoxazole and trimethoprim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations. There have been reports of marked but reversible nephrotoxicity with coadministration of sulfamethoxazole and trimethoprim and cyclosporine in renal transplant recipients. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding 25 mg weekly may develop megaloblastic anemia if sulfamethoxazole and trimethoprim is prescribed. The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Additional monitoring of blood glucose may be warranted. In the literature, a single case of toxic delirium has been reported after concomitant intake of sulfamethoxazole and trimethoprim and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported. In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole and trimethoprim and an angiotensin converting enzyme inhibitor. 8,9 Drug/Laboratory Test Interactions Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA). The presence of sulfamethoxazole and trimethoprim may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Sulfamethoxazole was not carcinogenic when assessed in a 26-week tumorigenic mouse (Tg-rasH2) study at doses up to 400 mg/kg/day sulfamethoxazole; equivalent to 2.4-fold the human systemic exposure (at a daily dose of 800 mg sulfamethoxazole b.i.d. ). Mutagenesis In vitro reverse mutation bacterial tests according to the standard protocol have not been performed with sulfamethoxazole and trimethoprim in combination. An in vitro chromosomal aberration test in human lymphocytes with sulfamethoxazole and trimethoprim was negative. In in vitro and in vivo tests in animal species, sulfamethoxazole and trimethoprim did not damage chromosomes. In vivo micronucleus assays were positive following oral administration of sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities. Sulfamethoxazole alone was positive in an in vitro reverse mutation bacterial assay and in in vitro micronucleus assays using cultured human lymphocytes. Trimethoprim alone was negative in in vitro reverse mutation bacterial assays and in in vitro chromosomal aberration assays with Chinese Hamster ovary or lung cells with or without S9 activation. In in vitro Comet, micronucleus and chromosomal damage assays using cultured human lymphocytes, trimethoprim was positive. In mice following oral administration of trimethoprim, no DNA damage in Comet assays of liver, kidney, lung, spleen, or bone marrow was recorded. Impairment of Fertility No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim, doses roughly two times the recommended human daily dose on a body surface area basis. Pregnancy While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell, 10 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter. Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenic Effects Pregnancy Category D Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic studies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple statistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures varied between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim exposure and specific malformations. Animal Data In rats, oral doses of either 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates. These doses are approximately 5 and 6 times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss (dead and resorbed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of trimethoprim and sulfamethoxazole in breast milk are approximately 2 to 5% of the recommended daily dose for infants over 2 months of age. Caution should be exercised when sulfamethoxazole and trimethoprim is administered to a nursing woman, especially when breastfeeding, jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use Sulfamethoxazole and trimethoprim is contraindicated for infants younger than 2 months of age (see INDICATIONS and CONTRAINDICATIONS sections). Geriatric Use Clinical studies of sulfamethoxazole and trimethoprim did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression (see WARNINGS and ADVERSE REACTIONS sections), a specific decrease in platelets (with or without purpura), and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see DOSAGE AND ADMINISTRATION section). The trimethoprim component of sulfamethoxazole and trimethoprim may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels. Sulfamethoxazole and trimethoprim tablets contain 0.45 mg sodium (0.02 mEq) of sodium per tablet. Sulfamethoxazole and trimethoprim DS tablets contain 0.9 mg (0.04 mEq) of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects (see CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics )."],"how_supplied":["HOW SUPPLIED Sulfamethoxazole and Trimethoprim Tablets USP, 400 mg/80 mg are white to off-white circular, beveled edge uncoated tablets, debossed with “H 48” on one side and deep break line on the other side. Sulfamethoxazole and Trimethoprim Tablets USP, 800 mg/160 mg are white to off-white oval, beveled edge uncoated tablets, debossed with “H 49” on one side and deep break line on other side. 55700-611-10 55700-611-14 55700-611-20 55700-611-28 Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59° to 86°F) [see USP Controlled Room Temperature]. DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER."],"geriatric_use":["Geriatric Use Clinical studies of sulfamethoxazole and trimethoprim did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression (see WARNINGS and ADVERSE REACTIONS sections), a specific decrease in platelets (with or without purpura), and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions (see DOSAGE AND ADMINISTRATION section). The trimethoprim component of sulfamethoxazole and trimethoprim may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of sulfamethoxazole and trimethoprim treatment is recommended to help lower potassium serum levels. Sulfamethoxazole and trimethoprim tablets contain 0.45 mg sodium (0.02 mEq) of sodium per tablet. Sulfamethoxazole and trimethoprim DS tablets contain 0.9 mg (0.04 mEq) of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects (see CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics )."],"pediatric_use":["Pediatric Use Sulfamethoxazole and trimethoprim is contraindicated for infants younger than 2 months of age (see INDICATIONS and CONTRAINDICATIONS sections)."],"effective_time":"20241217","nursing_mothers":["Nursing Mothers Levels of trimethoprim and sulfamethoxazole in breast milk are approximately 2 to 5% of the recommended daily dose for infants over 2 months of age. Caution should be exercised when sulfamethoxazole and trimethoprim is administered to a nursing woman, especially when breastfeeding, jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus."],"laboratory_tests":["Laboratory Tests Complete blood counts should be done frequently in patients receiving sulfamethoxazole and trimethoprim; if a significant reduction in the count of any formed blood element is noted, sulfamethoxazole and trimethoprim should be discontinued. Urinalyses with careful microscopic examination and renal function tests should be performed during therapy, particularly for those patients with impaired renal function."],"pharmacokinetics":["Geriatric Pharmacokinetics The pharmacokinetics of sulfamethoxazole 800 mg and trimethoprim 160 mg were studied in 6 geriatric subjects (mean age: 78.6 years) and 6 young healthy subjects (mean age: 29.3 years) using a non-U.S. approved formulation. Pharmacokinetic values for sulfamethoxazole in geriatric subjects were similar to those observed in young adult subjects. The mean renal clearance of trimethoprim was significantly lower in geriatric subjects compared with young adult subjects (19 mL/h/kg vs. 55 mL/h/kg). However, after normalizing by body weight, the apparent total body clearance of trimethoprim was on average 19% lower in geriatric subjects compared with young adult subjects. 3"],"adverse_reactions":["ADVERSE REACTIONS The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, anorexia) and allergic skin reactions (such as rash and urticaria). FATALITIES ASSOCIATED WITH THE ADMINISTRATION OF SULFONAMIDES, ALTHOUGH RARE, HAVE OCCURRED DUE TO SEVERE REACTIONS, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS (SEE WARNINGS SECTION). Hematologic Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, methemoglobinemia, eosinophilia. Allergic Reactions Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like syndrome, generalized allergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria and rash. In addition, periarteritis nodosa and systemic lupus erythematosus have been reported. Gastrointestinal Hepatitis (including cholestatic jaundice and hepatic necrosis), elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, pancreatitis, stomatitis, glossitis, nausea, emesis, abdominal pain, diarrhea, anorexia. Genitourinary Renal failure, interstitial nephritis, BUN and serum creatinine elevation, toxic nephrosis with oliguria and anuria, crystalluria and nephrotoxicity in association with cyclosporine. Metabolic and Nutritional Hyperkalemia, hyponatremia ( see PRECAUTIONS: Electrolyte Abnormalities ). Neurologic Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache. Psychiatric Hallucinations, depression, apathy, nervousness. Endocrine The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides) and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. Diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides. Musculoskeletal Arthralgia and myalgia. Isolated cases of rhabdomyolysis have been reported with sulfamethoxazole and trimethoprim, mainly in AIDS patients. Respiratory Cough, shortness of breath and pulmonary infiltrates (see WARNINGS ). Miscellaneous Weakness, fatigue, insomnia. Postmarketing Experience The following adverse reactions have been identified during post-approval use of trimethoprim-sulfamethoxazole. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Thrombotic thrombocytopenia purpura Idiopathic thrombocytopenic purpura QT prolongation resulting in ventricular tachycardia and torsade de pointes"],"contraindications":["CONTRAINDICATIONS Sulfamethoxazole and trimethoprim tablets are contraindicated in patients with a known hypersensitivity to trimethoprim or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency. Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. Sulfamethoxazole and trimethoprim tablets are also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored."],"drug_interactions":["Drug Interactions Potential for Sulfamethoxazole and Trimethoprim to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Caution is recommended when sulfamethoxazole and trimethoprim is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2. In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. It has been reported that sulfamethoxazole and trimethoprim may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin (a CYP2C9 substrate). This interaction should be kept in mind when sulfamethoxazole and trimethoprim is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Sulfamethoxazole and trimethoprim may inhibit the hepatic metabolism of phenytoin (a CYP2C9 substrate). Sulfamethoxazole and trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations. There have been reports of marked but reversible nephrotoxicity with coadministration of sulfamethoxazole and trimethoprim and cyclosporine in renal transplant recipients. Increased digoxin blood levels can occur with concomitant sulfamethoxazole and trimethoprim therapy, especially in elderly patients. Serum digoxin levels should be monitored. Increased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding 25 mg weekly may develop megaloblastic anemia if sulfamethoxazole and trimethoprim is prescribed. The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. Sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (e.g., pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (e.g., glipizide and glyburide) or eliminated renally via OCT2 (e.g., metformin). Additional monitoring of blood glucose may be warranted. In the literature, a single case of toxic delirium has been reported after concomitant intake of sulfamethoxazole and trimethoprim and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported. In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole and trimethoprim and an angiotensin converting enzyme inhibitor. 8,9"],"general_precautions":["Development of Drug Resistant Bacteria Prescribing sulfamethoxazole and trimethoprim tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Folate Deficiency Sulfamethoxazole and trimethoprim should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency (e.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with malabsorption syndrome, and patients in malnutrition states) and to those with severe allergies or bronchial asthma. Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure. These effects are reversible by folinic acid therapy. Hemolysis In glucose-6-phosphate dehydrogenase deficient individuals, hemolysis may occur. This reaction is frequently dose-related (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ). Hypoglycemia Cases of hypoglycemia in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk. Phenylalanine Metabolism Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction. Porphyria and Hypothyroidism As with all drugs containing sulfonamides, caution is advisable in patients with porphyria or thyroid dysfunction."],"teratogenic_effects":["While there are no large, well-controlled studies on the use of sulfamethoxazole and trimethoprim in pregnant women, Brumfitt and Pursell, 10 in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or sulfamethoxazole and trimethoprim. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving sulfamethoxazole and trimethoprim. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral sulfamethoxazole and trimethoprim at the time of conception or shortly thereafter. Because sulfamethoxazole and trimethoprim may interfere with folic acid metabolism, sulfamethoxazole and trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenic Effects Pregnancy Category D Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic studies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple statistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures varied between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim exposure and specific malformations. Animal Data In rats, oral doses of either 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates. These doses are approximately 5 and 6 times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when 512 mg/kg of sulfamethoxazole was used in combination with 128 mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss (dead and resorbed conceptuses) was associated with doses of trimethoprim 6 times the human therapeutic dose based on body surface area."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized in humans to at least 5 metabolites: the N 4 -acetyl-, N 4 -hydroxy-, 5-methylhydroxy-, N 4 -acetyl-5-methylhydroxy-sulfamethoxazole metabolites, and an N-glucuronide conjugate. The formulation of N 4 -hydroxy metabolite is mediated via CYP2C9. Trimethoprim is metabolized in vitro to 11 different metabolites, of which, five are glutathione adducts and six are oxidative metabolites, including the major metabolites, 1- and 3-oxides and the 3- and 4-hydroxy derivatives. The free forms of sulfamethoxazole and trimethoprim are considered to be the therapeutically active forms. In vitro studies suggest that trimethoprim is a substrate of P-glycoprotein, OCT1 and OCT2, and that sulfamethoxazole is not a substrate of P-glycoprotein. Approximately 70% of sulfamethoxazole and 44% of trimethoprim are bound to plasma proteins. The presence of 10 mg percent sulfamethoxazole in plasma decreases the protein binding of trimethoprim by an insignificant degree; trimethoprim does not influence the protein binding of sulfamethoxazole. Peak blood levels for the individual components occur 1 to 4 hours after oral administration. The mean serum half-lives of sulfamethoxazole and trimethoprim are 10 and 8 to 10 hours, respectively. However, patients with severely impaired renal function exhibit an increase in the half-lives of both components, requiring dosage regimen adjustment (see DOSAGE AND ADMINISTRATION section). Detectable amounts of sulfamethoxazole and trimethoprim are present in the blood 24 hours after drug administration. During administration of 800 mg sulfamethoxazole and 160 mg trimethoprim b.i.d., the mean steady-state plasma concentration of trimethoprim was 1.72 mcg/mL. The steady-state mean plasma levels of free and total sulfamethoxazole were 57.4 mcg/mL and 68 mcg/mL, respectively. These steady-state levels were achieved after three days of drug administration. 1 Excretion of sulfamethoxazole and trimethoprim is primarily by the kidneys through both glomerular filtration and tubular secretion. Urine concentrations of both sulfamethoxazole and trimethoprim are considerably higher than are the concentrations in the blood. The average percentage of the dose recovered in urine from 0 to 72 hours after a single oral dose of sulfamethoxazole and trimethoprim is 84.5% for total sulfonamide and 66.8% for free trimethoprim. Thirty percent of the total sulfonamide is excreted as free sulfamethoxazole, with the remaining as N 4 -acetylated metabolite. 2 When administered together as sulfamethoxazole and trimethoprim, neither sulfamethoxazole nor trimethoprim affects the urinary excretion pattern of the other. Both sulfamethoxazole and trimethoprim distribute to sputum, vaginal fluid and middle ear fluid; trimethoprim also distributes to bronchial secretion, and both pass the placental barrier and are excreted in human milk. Geriatric Pharmacokinetics The pharmacokinetics of sulfamethoxazole 800 mg and trimethoprim 160 mg were studied in 6 geriatric subjects (mean age: 78.6 years) and 6 young healthy subjects (mean age: 29.3 years) using a non-U.S. approved formulation. Pharmacokinetic values for sulfamethoxazole in geriatric subjects were similar to those observed in young adult subjects. The mean renal clearance of trimethoprim was significantly lower in geriatric subjects compared with young adult subjects (19 mL/h/kg vs. 55 mL/h/kg). However, after normalizing by body weight, the apparent total body clearance of trimethoprim was on average 19% lower in geriatric subjects compared with young adult subjects. 3 Microbiology Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. Thus, sulfamethoxazole and trimethoprim blocks two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria. In vitro studies have shown that bacterial resistance develops more slowly with both sulfamethoxazole and trimethoprim in combination than with either sulfamethoxazole or trimethoprim alone. Sulfamethoxazole and trimethoprim have been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive microorganisms Streptococcus pneumoniae Aerobic gram-negative microorganisms Escherichia coli (including susceptible enterotoxigenic strains implicated in traveler's diarrhea) Klebsiella species Enterobacter species Haemophilus influenzae Morganella morganii Proteus mirabilis Proteus vulgaris Shigella flexneri Shigella sonnei Other Organisms Pneumocystis jiroveci Susceptibility Testing Methods When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment. Dilution Techniques Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth or agar) 4, 15 . The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Techniques Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method 14, 15 . This procedure uses paper disks impregnated with 1.25/23.75 mcg of trimethoprim and sulfamethoxazole to test the susceptibility of microorganisms to trimethoprim and sulfamethoxazole. The disc diffusion interpretive criteria are provided in Table 1. Table 1: Susceptibility Test Interpretive Criteria for Trimethoprim and Sulfamethoxazole Bacteria Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm) S I R S I R Enterobacteriaceae ≤ 2/38 - ≥ 4/76 ≥ 16 11 – 15 ≤ 10 Haemophilus influenzae ≤ 0.5/9.5 1/19 – 2/38 ≥ 4/76 ≥ 16 11 – 15 ≤ 10 Streptococcus pneumoniae ≤ 0.5/9.5 1/19 – 2/38 ≥ 4/76 ≥ 19 16 – 18 ≤ 15 A report of Susceptible indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the site of infection necessary to inhibit growth of the pathogen. A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay and the techniques of the individuals performing the test 4, 14, 15 . Standard trimethoprim and sulfamethoxazole powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 1.25/23.75 mcg trimethoprim and sulfamethoxazole disk the criteria in Table 2 should be achieved. Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Trimethoprim and Sulfamethoxazole QC Strain Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm) Escherichia coli ATCC 25922 ≤ 0.5/9.5 23–29 Haemophilus influenzae ATCC 49247 0.03/0.59 – 0.25/4.75 24–32 Streptococcus pneumoniae ATCC 49619 0.12/2.4 – 1/19 20–28"],"indications_and_usage":["INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim tablets offer some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets, USP in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets, USP are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets, USP could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis jiroveci Pneumonia For the treatment of documented Pneumocystis jiroveci pneumonia and for prophylaxis against P. jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing P. jiroveci pneumonia. Traveler's Diarrhea in Adults For the treatment of traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli."],"nonteratogenic_effects":["Nonteratogenic Effects See CONTRAINDICATIONS section."],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs including sulfamethoxazole and trimethoprim tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When sulfamethoxazole and trimethoprim tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance, and will not be treatable by sulfamethoxazole and trimethoprim tablets or other antibacterial drugs in the future. Patients should be instructed to maintain an adequate fluid intake in order to prevent crystalluria and stone formation. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible."],"spl_unclassified_section":["Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Sulfamethoxazole and trimethoprim tablets are contraindicated in pediatric patients less than 2 months of age. Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children Adults The usual adult dosage in the treatment of urinary tract infections is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet or 2 sulfamethoxazole and trimethoprim tablets every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. Children The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage: Children 2 months of age or older: Weight Dose–every 12 hours lb kg Tablets 22 44 66 88 10 20 30 40 – 1 1½ 2 or 1 DS tablet For Patients with Impaired Renal Function When renal function is impaired, a reduced dosage should be employed using the following table: Creatinine Clearance (mL/min) Recommended Dosage Regimen Above 30 15–30 Below 15 Usual standard regimen ½ the usual regimen Use not recommended Acute Exacerbations of Chronic Bronchitis in Adults The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet or 2 sulfamethoxazole and trimethoprim tablets every 12 hours for 14 days. Pneumocystis Jiroveci Pneumonia Treatment Adults and Children The recommended dosage for treatment of patients with documented Pneumocystis jiroveci pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. 11 The following table is a guideline for the upper limit of this dosage: Weight Dose–every 6 hours lb kg Tablets 18 35 53 70 88 106 141 176 8 16 24 32 40 48 64 80 – 1 1½ 2 or 1 DS tablet 2½ 3 or 1½ DS tablets 4 or 2 DS tablets 5 or 2½ DS tablets For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table. Prophylaxis Adults The recommended dosage for prophylaxis in adults is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet daily. 12 Children For children, the recommended dose is 750 mg/m 2 /day sulfamethoxazole with 150 mg/m 2 /day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim. 13 The following table is a guideline for the attainment of this dosage in children: Body Surface Area Dose–every 12 hours (m 2 ) Tablets 0.26 0.53 1.06 – ½ 1 Traveler's Diarrhea in Adults For the treatment of traveler’s diarrhea, the usual adult dosage is 1 sulfamethoxazole and trimethoprim DS (double strength) tablet or 2 sulfamethoxazole and trimethoprim tablets every 12 hours for 5 days."],"spl_product_data_elements":["Sulfamethoxazole and Trimethoprim Sulfamethoxazole and Trimethoprim SULFAMETHOXAZOLE SULFAMETHOXAZOLE TRIMETHOPRIM TRIMETHOPRIM DOCUSATE SODIUM MAGNESIUM STEARATE STARCH, CORN SODIUM BENZOATE SODIUM STARCH GLYCOLATE TYPE A POTATO White to Off-white Beveled Edge H;49"],"clinical_pharmacology_table":["
Table 1: Susceptibility Test Interpretive Criteria for Trimethoprim and Sulfamethoxazole
Bacteria Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm)
S I R S I R
Enterobacteriaceae ≤ 2/38 - ≥ 4/76 ≥ 16 11 – 15 ≤ 10
Haemophilus influenzae ≤ 0.5/9.5 1/19 – 2/38 ≥ 4/76 ≥ 16 11 – 15 ≤ 10
Streptococcus pneumoniae ≤ 0.5/9.5 1/19 – 2/38 ≥ 4/76 ≥ 19 16 – 18 ≤ 15
","
Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Trimethoprim and Sulfamethoxazole
QC Strain Minimal Inhibitory Concentration (mcg/mL) Zone Diameter (mm)
Escherichia coli ATCC 25922 ≤ 0.5/9.5 23–29
Haemophilus influenzae ATCC 49247 0.03/0.59 – 0.25/4.75 24–32
Streptococcus pneumoniae ATCC 49619 0.12/2.4 – 1/19 20–28
"],"dosage_and_administration_table":["
Weight Dose–every 12 hours
lb kg Tablets
22 44 66 88 10 20 30 40 – 1 1½ 2 or 1 DS tablet
","
Creatinine Clearance (mL/min) Recommended Dosage Regimen
Above 30 15–30 Below 15 Usual standard regimen ½ the usual regimen Use not recommended
","
Weight Dose–every 6 hours
lb kg Tablets
18 35 53 70 88 106 141 176 8 16 24 32 40 48 64 80 – 1 1½ 2 or 1 DS tablet 2½ 3 or 1½ DS tablets 4 or 2 DS tablets 5 or 2½ DS tablets
","
Body Surface Area Dose–every 12 hours
(m2) Tablets
0.26 0.53 1.06 – ½ 1
"],"package_label_principal_display_panel":["image description"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA). The presence of sulfamethoxazole and trimethoprim may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Sulfamethoxazole was not carcinogenic when assessed in a 26-week tumorigenic mouse (Tg-rasH2) study at doses up to 400 mg/kg/day sulfamethoxazole; equivalent to 2.4-fold the human systemic exposure (at a daily dose of 800 mg sulfamethoxazole b.i.d. ). Mutagenesis In vitro reverse mutation bacterial tests according to the standard protocol have not been performed with sulfamethoxazole and trimethoprim in combination. An in vitro chromosomal aberration test in human lymphocytes with sulfamethoxazole and trimethoprim was negative. In in vitro and in vivo tests in animal species, sulfamethoxazole and trimethoprim did not damage chromosomes. In vivo micronucleus assays were positive following oral administration of sulfamethoxazole and trimethoprim. Observations of leukocytes obtained from patients treated with sulfamethoxazole and trimethoprim revealed no chromosomal abnormalities. Sulfamethoxazole alone was positive in an in vitro reverse mutation bacterial assay and in in vitro micronucleus assays using cultured human lymphocytes. Trimethoprim alone was negative in in vitro reverse mutation bacterial assays and in in vitro chromosomal aberration assays with Chinese Hamster ovary or lung cells with or without S9 activation. In in vitro Comet, micronucleus and chromosomal damage assays using cultured human lymphocytes, trimethoprim was positive. In mice following oral administration of trimethoprim, no DNA damage in Comet assays of liver, kidney, lung, spleen, or bone marrow was recorded. Impairment of Fertility No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim, doses roughly two times the recommended human daily dose on a body surface area basis."]},"tags":[{"label":"Dihydrofolate Reductase Inhibitor Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dihydrofolate reductase","category":"target"},{"label":"DHFR","category":"gene"},{"label":"SLC22A1","category":"gene"},{"label":"J01EA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Ophthalmic","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Suspension","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Acute exacerbation of chronic bronchitis","category":"indication"},{"label":"Acute otitis media","category":"indication"},{"label":"Bacterial conjunctivitis","category":"indication"},{"label":"Bacterial urinary infection","category":"indication"},{"label":"Blepharoconjunctivitis","category":"indication"},{"label":"Escherichia coli urinary tract infection","category":"indication"},{"label":"Dr Reddys Labs Sa","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Urinary","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Cytochrome P-450 CYP2C8 Inhibitors","category":"pharmacology"},{"label":"Cytochrome P-450 Enzyme Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Folic Acid Antagonists","category":"pharmacology"},{"label":"Metabolic Side Effects of Drugs and Substances","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"6766 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"6008 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5764 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5506 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5501 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"4886 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"4871 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"4466 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"4310 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"4162 reports"}],"drugInteractions":[{"url":"/drug/pralatrexate","drug":"pralatrexate","action":"Avoid combination","effect":"May interact with Pralatrexate","source":"DrugCentral","drugSlug":"pralatrexate"}],"commonSideEffects":[{"effect":"abdominal pain","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"diarrhea","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"vomiting","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"rash","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"pruritus","drugRate":"reported","severity":"unknown"},{"effect":"exfoliative dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"epigastric distress","drugRate":"reported","severity":"unknown"},{"effect":"nausea","drugRate":"reported","severity":"unknown"},{"effect":"glossitis","drugRate":"reported","severity":"unknown"},{"effect":"thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"megaloblastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"methemoglobinemia","drugRate":"reported","severity":"unknown"},{"effect":"hyperkalemia","drugRate":"reported","severity":"unknown"},{"effect":"hyponatremia","drugRate":"reported","severity":"unknown"},{"effect":"fever","drugRate":"reported","severity":"unknown"},{"effect":"elevation of serum transaminase","drugRate":"reported","severity":"unknown"},{"effect":"elevation of serum bilirubin","drugRate":"reported","severity":"unknown"},{"effect":"increases in BUN","drugRate":"reported","severity":"unknown"},{"effect":"increases in serum creatinine levels","drugRate":"reported","severity":"unknown"}],"contraindications":["Anemia due to enzyme deficiency","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Folic acid deficiency","Kidney disease","Megaloblastic anemia due to folate deficiency","Neutropenic disorder","Porphyria","Pseudomembranous enterocolitis","Third trimester pregnancy","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"Trimethoprim has been shown to be teratogenic in the rat when given in doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses six times the human therapeutic dose. While there are no large, well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell,3 in retrospective study, reported the outcome of 186 pregnancies.","Geriatric use":"Clinical studies of trimethoprim tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience4,5has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function.","Paediatric use":"The safety of trimethoprim has not been established in pediatric patients below the age of 6 months. The effectiveness of trimethoprim in the treatment of acute otitis media has not been established in patients below the age of 6 months.","Hepatic impairment":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function."}},"trials":[],"aliases":[],"company":"Dr Reddys Labs Sa","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.6380/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$598","description":"TRIMETHOPRIM 100 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TRIMETHOPRIM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:41:00.719903+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Trimethoprim","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:41:07.832180+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:41:06.369194+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:40:59.843194+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIMETHOPRIM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:41:06.768684+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:54.124746+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:54.124776+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:54.124783+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:41:08.302198+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial dihydrofolate reductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:07.832119+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201080/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:07.489139+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090624","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:40:54.124787+00:00"}},"allNames":["trimethoprim","trimethoprim sulfate","trimethoprim hydrochloride","trimethioprim","trimetoprim","trimopan","trimethoprim HCl","Bactrim (combination)","Bactrim DS (combination)","Polytrim (combination)","SULFATRIM (combination)","Sulfamethoxazole and Trimethoprim (combination)"],"offLabel":[],"synonyms":["trimethoprim","trimethoprim sulfate","trimethoprim hydrochloride","trimethioprim","trimetoprim","trimopan","trimethoprim HCl"],"timeline":[{"date":"1973-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MUTUAL PHARM to Dr Reddys Labs Sa"},{"date":"1973-07-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Mutual Pharm)"},{"date":"1982-07-30","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Dr Reddys Labs Sa)"},{"date":"1986-01-22","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Trimethoprim is a dihydrofolate reductase inhibitor antibacterial small molecule originally developed by Mutual Pharm and currently owned by Dr Reddys Labs Sa. It targets dihydrofolate reductase, an enzyme essential for bacterial DNA synthesis, thereby inhibiting bacterial growth. Trimethoprim is approved to treat various bacterial infections, including urinary tract infections, bronchitis, and conjunctivitis. The drug has a high bioavailability of 98% and a half-life of 9.6 hours. It is off-patent, with multiple generic manufacturers available.","approvals":[{"date":"1973-07-30","orphan":false,"company":"MUTUAL PHARM","regulator":"FDA"}],"brandName":"Trimethoprim","ecosystem":[{"indication":"Acute exacerbation of chronic bronchitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefditoren pivoxil","slug":"cefditoren-pivoxil","company":"Vansen Pharma"}],"globalPrevalence":null},{"indication":"Acute otitis media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"}],"globalPrevalence":709000000},{"indication":"Bacterial conjunctivitis","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"besifloxacin","slug":"besifloxacin","company":"Bausch And Lomb"},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"}],"globalPrevalence":null},{"indication":"Bacterial urinary infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"avibactam","slug":"avibactam","company":"Cerexa Inc"}],"globalPrevalence":null},{"indication":"Blepharoconjunctivitis","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"bacitracin","slug":"bacitracin","company":"Pharmacia And Upjohn"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Escherichia coli urinary tract infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"betaine","slug":"betaine","company":"Rare Dis Therap"}],"globalPrevalence":null},{"indication":"Haemophilus Influenzae Acute Otitis Media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"}],"globalPrevalence":null},{"indication":"Haemophilus Influenzae Chronic Bronchitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefaclor","slug":"cefaclor","company":""},{"name":"cefditoren pivoxil","slug":"cefditoren-pivoxil","company":"Vansen Pharma"}],"globalPrevalence":null}],"mechanism":{"target":"Dihydrofolate reductase","targets":[{"gene":"DHFR","source":"DrugCentral","target":"Dihydrofolate reductase","protein":"Dihydrofolate reductase"},{"gene":"SLC22A1","source":"DrugCentral","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1"}],"moaClass":"Cytochrome P450 2C8 Inhibitors","modality":"Small Molecule","drugClass":"Sulfonamide Antimicrobial [EPC]","explanation":"","oneSentence":"","technicalDetail":"Trimethoprim inhibits dihydrofolate reductase, an enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate, a necessary precursor for thymidylate synthesis and subsequently DNA replication in bacteria."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Trimethoprim","title":"Trimethoprim","extract":"Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travellers' diarrhoea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally.","wiki_history":"==History==\nTrimethoprim was first used in 1962. In 1972, it was used as a prophylactic treatment for urinary tract infections in Finland.\n\nIts name is derived from trimethyloxy-pyrimidine.\n\n"},"commercial":{"launchDate":"1973","_launchSource":"DrugCentral (FDA 1973-07-30, MUTUAL PHARM)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2755","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TRIMETHOPRIM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIMETHOPRIM","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Trimethoprim","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:04:14.018340","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:10.858394+00:00","fieldsConflicting":5,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"trimethoprim","indications":{"approved":[{"name":"Acute exacerbation of chronic bronchitis","source":"DrugCentral","snomedId":425748003,"regulator":"FDA","eligibility":null},{"name":"Acute otitis media","source":"DrugCentral","snomedId":3110003,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":709000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2026 (PMID:41640273)"},{"name":"Bacterial conjunctivitis","source":"DrugCentral","snomedId":128350005,"regulator":"FDA","eligibility":null},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA","eligibility":null},{"name":"Blepharoconjunctivitis","source":"DrugCentral","snomedId":68659002,"regulator":"FDA","eligibility":null},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA","eligibility":{"age":null,"stage":null,"organisms":["Escherichia coli","Proteus mirabilis","Klebsiella pneumoniae","Enterobacter species","coagulase-negative Staphylococcus species","S. saprophyticus"],"biomarkers":null,"prior treatment":null}},{"name":"Haemophilus Influenzae Acute Otitis Media","source":"DrugCentral","snomedId":19021002,"regulator":"FDA","eligibility":null},{"name":"Haemophilus Influenzae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Infective otitis media","source":"DrugCentral","snomedId":312218008,"regulator":"FDA","eligibility":null},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA","eligibility":{"age":null,"stage":null,"organisms":["Klebsiella pneumoniae"],"biomarkers":null,"prior treatment":null}},{"name":"Morganella Morganii Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pneumocystis Carinii Pneumonia Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pneumocystosis jiroveci pneumonia","source":"DrugCentral","snomedId":415125002,"regulator":"FDA"},{"name":"Proteus urinary tract infection","source":"DrugCentral","snomedId":301012009,"regulator":"FDA"},{"name":"Shigellosis","source":"DrugCentral","snomedId":36188001,"regulator":"FDA"},{"name":"Staphylococcus Aureus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcus Pneumoniae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA"}],"offLabel":[{"name":"Bacterial endocarditis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Bacterial pneumonia","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":1064,"evidenceLevel":"strong"},{"name":"Brucellosis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Chancroid","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":74,"evidenceLevel":"strong"},{"name":"Chlamydial infection","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":60,"evidenceLevel":"strong"},{"name":"Cholera","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":330,"evidenceLevel":"strong"},{"name":"Chronic Bacterial Prostatitis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Diabetic Foot Infection","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":39,"evidenceLevel":"moderate"},{"name":"Diverticulitis of gastrointestinal tract","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Granuloma inguinale","source":"DrugCentral","drugName":"TRIMETHOPRIM","evidenceCount":17,"evidenceLevel":"moderate"},{"name":"Infection of bone","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Listeria meningitis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Lymphogranuloma venereum","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Meningococcus carrier","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Nocardiosis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Paracoccidioidomycosis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Paratyphoid fever","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Pertussis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Postexposure Plague Prophylaxis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Sinusitis","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Toxoplasmosis Prevention","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Toxoplasmosis associated with acquired immunodeficiency syndrome","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Typhoid fever","source":"DrugCentral","drugName":"TRIMETHOPRIM"},{"name":"Whipple's disease","source":"DrugCentral","drugName":"TRIMETHOPRIM"}],"pipeline":[]},"currentOwner":"Dr Reddys Labs Sa","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT07501065","phase":"PHASE4","title":"Prophylactic Antibiotics for Outpatient Urethral Bulking","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-06","conditions":["Urinary Tract Infections","Stress Urinary Incontinence","Urinary Incontinence"],"enrollment":150,"completionDate":"2028-12"},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":["Mycobacterium Abscessus Pulmonary Disease","Mycobacterium Abscessus Infection","Non-Tuberculous Mycobacterial (NTM) Infections","Non-Tuberculous Mycobacteria Pulmonary Disease"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":["Urinary Tract Infections"],"enrollment":318,"completionDate":"2026-12"},{"nctId":"NCT01631617","phase":"PHASE2","title":"Effects of Treatments on Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2012-09-18","conditions":["Eczema","Dermatitis","Skin Diseases, Genetic","Dermatitis, Atopic","Skin Diseases"],"enrollment":130,"completionDate":"2027-01-01"},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":["Gram-negative Bacteremia"],"enrollment":1030,"completionDate":"2027-06-30"},{"nctId":"NCT06397781","phase":"PHASE4","title":"Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2031-01-01","conditions":["Atopic Dermatitis"],"enrollment":100,"completionDate":"2039-12"},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Small Intestine Bacterial Overgrowth"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT07202949","phase":"PHASE2","title":"A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2026-02-28","conditions":["Chronic Urinary Tract Infection"],"enrollment":192,"completionDate":"2027-11"},{"nctId":"NCT04851015","phase":"PHASE3","title":"Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2025-11-28","conditions":["Pneumocystis","Pneumocystis Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystis Infections","Pneumocystis Carinii Infection","Pneumocystosis; Pneumonia (Etiology)","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystosis Associated With AIDS"],"enrollment":416,"completionDate":"2030-12-31"},{"nctId":"NCT03489629","phase":"PHASE2","title":"STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-04-03","conditions":["Cystic Fibrosis"],"enrollment":37,"completionDate":"2026-01-31"},{"nctId":"NCT05274672","phase":"PHASE4","title":"Role of Prophylactic Postoperative Antibiotics in HoLEP","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2023-03-01","conditions":["Benign Prostatic Hyperplasia","Urinary Tract Infections"],"enrollment":0,"completionDate":"2025-02-20"},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":["Candidemia","Mycoses","Fungal Infection","Fungemia","Invasive Candidiasis","Pneumocystis","Mold Infection","Invasive Fungal Disease","Prophylaxis of Invasive Fungal Infections","Aspergillus"],"enrollment":602,"completionDate":"2026-02"},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":["Gram-negative Bacteremia"],"enrollment":2500,"completionDate":"2028-04"},{"nctId":"NCT04263792","phase":"PHASE1","title":"[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-02-07","conditions":["Bacterial Infections"],"enrollment":20,"completionDate":"2027-01"},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":["Erectile Dysfunction","Penile Prosthesis Infection"],"enrollment":800,"completionDate":"2028-01-01"},{"nctId":"NCT03424525","phase":"PHASE1","title":"11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-02-01","conditions":["Bacterial Infections"],"enrollment":16,"completionDate":"2025-12-01"},{"nctId":"NCT07357103","phase":"PHASE4","title":"Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-03","conditions":["Pneumocystis","Pneumocystis Infection","Pneumocystis Carinii Infection","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystis Jirovecii Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystosis Associated With AIDS","Pneumocystosis; Pneumonia (Etiology)"],"enrollment":416,"completionDate":"2029-09"},{"nctId":"NCT07343934","phase":"PHASE1","title":"huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-02","conditions":["Relapsed or Refractory Follicular Lymphoma"],"enrollment":6,"completionDate":"2042-09"},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":["Osteomyelitis - Foot"],"enrollment":0,"completionDate":"2026-11"},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":["Age-Related Macular Degeneration"],"enrollment":42,"completionDate":"2026-06-30"},{"nctId":"NCT01388413","phase":"PHASE4","title":"Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-08","conditions":["Neurogenic Bladder","Urinary Tract Infection"],"enrollment":45,"completionDate":"2017-02"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT03637400","phase":"PHASE2","title":"Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2018-11-26","conditions":["Methicillin-resistant Staphylococcus Aureus","Skin Infection"],"enrollment":269,"completionDate":"2025-06-30"},{"nctId":"NCT05066854","phase":"NA","title":"INterest of the Negative Predictive Value of Integrons in Choosing a Narrow-spectrum Empirical anTibiotic Treatment vs Usual Empirical Antibiotic Treatment for Urinary Tract infectionS in the PEDiatric Emergency Department","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2022-10-18","conditions":["Urinary Tract Infections in Children"],"enrollment":36,"completionDate":"2025-11-17"},{"nctId":"NCT02539407","phase":"","title":"Population Pharmacokinetics of Anti-infectives in Critically Ill Children","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-11","conditions":["Pediatric Intensive Care Unit","Pediatric Immuno-hematology Department"],"enrollment":3000,"completionDate":"2028-12"},{"nctId":"NCT03919435","phase":"PHASE1,PHASE2","title":"TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2019-03-27","conditions":["Granulomatosis With Polyangiitis","Wegener Granulomatosis"],"enrollment":8,"completionDate":"2027-12-30"},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":["Non-Tuberculous Mycobacterial (NTM) Pneumonia","Mycobacterium Abscessus Infection"],"enrollment":1,"completionDate":"2027-10"},{"nctId":"NCT06536374","phase":"PHASE2","title":"Folate Study in Men With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT07224997","phase":"PHASE2","title":"Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections","status":"NOT_YET_RECRUITING","sponsor":"Hospital Civil de Guadalajara","startDate":"2025-12-01","conditions":["Acute Kidney Injuries","Acute Kidney Disease","Acute Kidney Injury (AKI)"],"enrollment":120,"completionDate":"2027-07-01"},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":["Immune Checkpoint Inhibitor-Related Colitis"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT07106125","phase":"PHASE4","title":"Antibiotics for Kidney Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-11","conditions":["Kidney Transplant","Urinary Tract Infection(UTI)","Antibiotic Prophylaxis","Remote Patient Monitoring","Feasibility Pilot Study"],"enrollment":50,"completionDate":"2029-01"},{"nctId":"NCT06706362","phase":"PHASE4","title":"Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":["Stress Urinary Incontinence"],"enrollment":138,"completionDate":"2027-10-15"},{"nctId":"NCT07202091","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":["Myeloma","Leukemia","Non Hodgkin's Lymphoma"],"enrollment":900,"completionDate":"2027-03-31"},{"nctId":"NCT07202078","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-07","conditions":["Myeloma","Non Hodgkin's Lymphoma","Leukemia"],"enrollment":900,"completionDate":"2027-03-31"},{"nctId":"NCT07202052","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":["Myeloma","Non-Hodgkin's Lymphoma","Leukemia"],"enrollment":900,"completionDate":"2027-03-31"},{"nctId":"NCT03915366","phase":"PHASE2,PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":["Pneumonia","HIV/AIDS","Tuberculosis","Cytomegalovirus Infections"],"enrollment":563,"completionDate":"2025-01-31"},{"nctId":"NCT05823467","phase":"NA","title":"What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2023-06-26","conditions":["Breast Cancer"],"enrollment":105,"completionDate":"2026-12-31"},{"nctId":"NCT05726318","phase":"PHASE4","title":"Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","status":"COMPLETED","sponsor":"Megan Bradley","startDate":"2023-02-17","conditions":["UTI"],"enrollment":70,"completionDate":"2024-08-02"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT04310930","phase":"PHASE2,PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":["Pulmonary Disease Due to Mycobacteria (Diagnosis)"],"enrollment":300,"completionDate":"2030-06-30"},{"nctId":"NCT04502095","phase":"PHASE4","title":"Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-09-02","conditions":["Bladder Carcinoma","Refractory Bladder Carcinoma","Urinary Tract Infection"],"enrollment":89,"completionDate":"2025-03-13"},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":["Retinal Detachment","Achilles Tendon","Aneurysm, Dissecting"],"enrollment":117911,"completionDate":"2018-06-04"},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":["Rhegmatogenous Retinal Detachment"],"enrollment":168,"completionDate":"2027-01-30"},{"nctId":"NCT06982105","phase":"PHASE4","title":"Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-05-20","conditions":["Methicillin Resistant Staphylococcus Aureus","Osteomyelitis Acute","Septic Arthritis","Orbital Cellulitis","Facial Cellulitis","Mastoiditis","Cervical Adenitis","Retropharyngeal Abscess","Peritonsillar Abscess"],"enrollment":100,"completionDate":"2027-06"},{"nctId":"NCT05696093","phase":"PHASE3","title":"Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-19","conditions":["Ventilator Associated Pneumonia"],"enrollment":628,"completionDate":"2026-12-31"},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":["Overactive Bladder (OAB)","Urinary Tract Infection (Diagnosis)"],"enrollment":164,"completionDate":"2027-01-01"},{"nctId":"NCT05835479","phase":"PHASE2","title":"Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults","status":"RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2023-11-14","conditions":["Pneumocystis Pneumonia"],"enrollment":50,"completionDate":"2025-08"},{"nctId":"NCT04884490","phase":"PHASE2,PHASE3","title":"The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-05-15","conditions":["COVID-19 Pneumonia"],"enrollment":94,"completionDate":"2021-11-14"},{"nctId":"NCT06881732","phase":"PHASE1","title":"Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP","status":"NOT_YET_RECRUITING","sponsor":"University of Melbourne","startDate":"2025-07","conditions":["Malaria Falciparum","Malaria Infection","Malaria Transmission"],"enrollment":2,"completionDate":"2026-07"},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":["Nephrolithiasis","Urinary Tract Infection (UTI)","Sepsis"],"enrollment":330,"completionDate":"2025-03"},{"nctId":"NCT05268120","phase":"NA","title":"MRSA Decolonization in Complicated Carriage","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-07-25","conditions":["MRSA"],"enrollment":211,"completionDate":"2028-05-01"},{"nctId":"NCT02944825","phase":"NA","title":"Antibiotic Prophylaxis With Routine Ureteral Stent Removal","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":["Urolithiasis","UTI"],"enrollment":80,"completionDate":"2025-03"},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":["Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit"],"enrollment":248,"completionDate":"2027-01"},{"nctId":"NCT03746106","phase":"PHASE4","title":"The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-01-28","conditions":["Vitamin B1 Deficiency","Thiamine Deficiency"],"enrollment":7,"completionDate":"2023-08-10"},{"nctId":"NCT06737016","phase":"PHASE3","title":"Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-11-01","conditions":["Posterior Urethral Valve"],"enrollment":50,"completionDate":"2026-11"},{"nctId":"NCT06207786","phase":"NA","title":"Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2024-09-01","conditions":["Skin Cancer","Skin Cancer Face","Malignant Cutaneous Adnexal Neoplasm"],"enrollment":0,"completionDate":"2030-05"},{"nctId":"NCT06691321","phase":"","title":"Caspofungin for Pneumocystis Pneumonia in PLWHIV.","status":"RECRUITING","sponsor":"Instituto Nacional de Enfermedades Respiratorias","startDate":"2023-08-01","conditions":["HIV-1-infection","Pneumocystis Pneumonia"],"enrollment":60,"completionDate":"2025-09-01"},{"nctId":"NCT05652374","phase":"PHASE4","title":"Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-10-20","conditions":["Recurrent Urinary Tract Infection"],"enrollment":100,"completionDate":"2027-10"},{"nctId":"NCT02096159","phase":"NA","title":"Prophylactic Antibiotics or Placebo After Hypospadias Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2014-03","conditions":["Hypospadias"],"enrollment":93,"completionDate":"2025-08"},{"nctId":"NCT06594133","phase":"","title":"Longitudinal and Cross-sectional Analysis of Pulmonary Microbiota in Lung Transplant Recipients Infected With Nocardia","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2023-01-01","conditions":["Nocardia Infections","Lung Transplantation"],"enrollment":68,"completionDate":"2024-09-01"},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":["Biliary Atresia","Cholangitis","Anti-Bacterial Agents"],"enrollment":356,"completionDate":"2027-07-31"},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":["Gram-negative Bacteremia"],"enrollment":174,"completionDate":"2024-08-10"},{"nctId":"NCT06499233","phase":"PHASE4","title":"Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-07-20","conditions":["Pneumonia, Pneumocystis","Autoimmune Inflammatory Rheumatic Disease","Autoimmune Diseases","Connective Tissue Disease","Prevention"],"enrollment":800,"completionDate":"2026-12-31"},{"nctId":"NCT05302531","phase":"PHASE1","title":"Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2022-12-09","conditions":["Short Bowel Syndrome","Infection, Bacterial"],"enrollment":10,"completionDate":"2025-02"},{"nctId":"NCT03633643","phase":"PHASE4","title":"Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-10-29","conditions":["Antimicrobial Prophylaxis in Prostate Surgery"],"enrollment":728,"completionDate":"2022-10-31"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT02164461","phase":"PHASE1","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","status":"COMPLETED","sponsor":"Advaxis, Inc.","startDate":"2015-03-04","conditions":["Effects of Immunotherapy","Metastatic/Recurrent Cervical Cancer","Cervical Adenocarcinoma","Cervical Adenosquamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Cervical Small Cell Carcinoma","Stage III Cervical Cancer","Stage IVA Cervical Cancer","Stage IVB Cervical Cancer"],"enrollment":12,"completionDate":"2017-03-08"},{"nctId":"NCT05843968","phase":"PHASE2","title":"Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome","status":"RECRUITING","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2023-01-29","conditions":["Nephrotic Syndrome in Children"],"enrollment":46,"completionDate":"2026-07-01"},{"nctId":"NCT05678621","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension","status":"RECRUITING","sponsor":"Monash University","startDate":"2022-11-30","conditions":["Haematological Malignancy","Hypogammaglobulinemia"],"enrollment":300,"completionDate":"2027-04"},{"nctId":"NCT05063422","phase":"PHASE1","title":"Retentive Strength of Denture Adhesives on Various RR Ridges","status":"COMPLETED","sponsor":"Altamash Institute of Dental Medicine","startDate":"2022-08-18","conditions":["Retentive Strength of Denture Adhesives"],"enrollment":24,"completionDate":"2023-08-17"},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":["Antibiotic Prophylaxis"],"enrollment":140,"completionDate":"2024-08-16"},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":["Staphylococcus Aureus"],"enrollment":265,"completionDate":"2023-06-30"},{"nctId":"NCT03920007","phase":"PHASE1,PHASE2","title":"Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atsena Therapeutics Inc.","startDate":"2019-09-12","conditions":["Leber Congenital Amaurosis","LCA","LCA1"],"enrollment":15,"completionDate":"2027-05-19"},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":["Overactive Bladder","Overactive Bladder Syndrome","Urge Incontinence","Urinary Incontinence, Urge"],"enrollment":100,"completionDate":"2023-06-08"},{"nctId":"NCT02773407","phase":"PHASE3","title":"Nepal Undifferentiated Febrile Illness Trial","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2016-05-23","conditions":["Undifferentiated Febrile Illness"],"enrollment":330,"completionDate":"2019-08-04"},{"nctId":"NCT05418777","phase":"PHASE1,PHASE2","title":"Treatment of Pneumocystis in COPD (the TOPIC Study)","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2022-09-28","conditions":["COPD Exacerbation Acute"],"enrollment":1,"completionDate":"2022-12-19"},{"nctId":"NCT03431168","phase":"PHASE2","title":"A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-03-07","conditions":["HIV","Pregnancy Malaria","Sexually Transmitted Infection"],"enrollment":308,"completionDate":"2022-01-01"},{"nctId":"NCT05199324","phase":"PHASE4","title":"Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2022-04-01","conditions":["Gram-negative Bacteraemia"],"enrollment":720,"completionDate":"2025-06-01"},{"nctId":"NCT04395365","phase":"PHASE3","title":"Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis","status":"UNKNOWN","sponsor":"University College, London","startDate":"2019-06-30","conditions":["Spontaneous Bacterial Peritonitis"],"enrollment":442,"completionDate":"2025-10"},{"nctId":"NCT03508921","phase":"PHASE4","title":"Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":["Overactive Bladder","Urinary Tract Infections"],"enrollment":22,"completionDate":"2022-06-01"},{"nctId":"NCT01140516","phase":"NA","title":"Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2010-07","conditions":["Hydronephrosis","Urinary Tract Infection"],"enrollment":160,"completionDate":"2024-09"},{"nctId":"NCT02021006","phase":"PHASE3","title":"Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2013-12","conditions":["Vesicoureteral Reflux","Renal Hypodysplasia, Nonsyndromic, 1","Chronic Kidney Disease"],"enrollment":292,"completionDate":"2025-01"},{"nctId":"NCT05224401","phase":"PHASE3","title":"Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs","status":"RECRUITING","sponsor":"Lund University","startDate":"2023-05-29","conditions":["Urinary Tract Infections","Bacteremia","Antibiotic Resistant Infection"],"enrollment":330,"completionDate":"2027-09-01"},{"nctId":"NCT05734794","phase":"PHASE3","title":"Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2023-02-09","conditions":["Nephrotic Syndrome in Children","Rituximab"],"enrollment":80,"completionDate":"2026-07-30"},{"nctId":"NCT04158713","phase":"PHASE3","title":"Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2019-11-11","conditions":["Pregnancy; HIV; Malaria"],"enrollment":898,"completionDate":"2022-08-30"},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":["Uterus Transplant"],"enrollment":0,"completionDate":"2018-07-24"},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":["Corneal Edema","Corneal Defect","Corneal Transplant","Penetrating KeratoPlasty","Anterior Chamber Inflammation","Ocular Pain","Intraocular Pressure"],"enrollment":36,"completionDate":"2023-01-04"},{"nctId":"NCT00976963","phase":"NA","title":"Single Dose Monurol for Treatment of Acute Cystitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2009-09-17","conditions":["Urinary Tract Infection"],"enrollment":300,"completionDate":"2016-12-27"},{"nctId":"NCT05438082","phase":"PHASE4","title":"Antibiotic Prophylaxis to Prevent Post-procedure UTI After VCUG","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2023-10","conditions":["Antibiotic Prophylaxis","Voiding Cystourethrogram","Febrile Urinary Tract Infection"],"enrollment":84,"completionDate":"2024-12"},{"nctId":"NCT00324922","phase":"PHASE3","title":"Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-05-01","conditions":["Osteomyelitis","Methicillin-resistant Staphylococcus Aureus"],"enrollment":2,"completionDate":"2007-05-01"},{"nctId":"NCT02853604","phase":"PHASE3","title":"Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Advaxis, Inc.","startDate":"2015-12-15","conditions":["High Risk Cervical Cancer","Advanced Cervical Cancer"],"enrollment":110,"completionDate":"2019-07-31"},{"nctId":"NCT03187834","phase":"PHASE4","title":"Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-07-04","conditions":["Child Development"],"enrollment":252,"completionDate":"2019-09-01"},{"nctId":"NCT05702762","phase":"PHASE2","title":"Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting","status":"UNKNOWN","sponsor":"Mercy Health Ohio","startDate":"2022-10-01","conditions":["Urinary Tract Infections"],"enrollment":160,"completionDate":"2024-06-30"},{"nctId":"NCT05575427","phase":"PHASE4","title":"Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-11-24","conditions":["Hospital Infections"],"enrollment":112,"completionDate":"2024-11-01"},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"},{"nctId":"NCT05384197","phase":"PHASE3","title":"Enhanced Versus Extended Preoperative Antibiotic Prophylaxis Regimens for Retrograde Intrarenal Surgery in High Infectious Risk Patients","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-05-01","conditions":["Renal Stone"],"enrollment":280,"completionDate":"2023-07-01"},{"nctId":"NCT05577273","phase":"NA","title":"Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Omri Schwarztuch Gildor","startDate":"2018-08-14","conditions":["Urologic Diseases","Urinary Tract Disease"],"enrollment":1000,"completionDate":"2023-08-31"},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":["Open-angle Glaucoma"],"enrollment":53,"completionDate":"2019-11-08"},{"nctId":"NCT01650558","phase":"NA","title":"Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-11","conditions":["HIV"],"enrollment":1499,"completionDate":"2018-07-31"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Solution, Solution/ Drops, Suspension","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Sulfamethoxazole and Trimethoprim"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Sulfamethoxazole and Trimethoprim"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"POLYMYXIN B SULFATE AND TRIMETHOPRIM"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Polymyxin B Sulfate and Trimethoprim"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Trimethoprim sulfate and Polymyxin B sulfate"},{"form":"SOLUTION","route":"ORAL","productName":"Primsol"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Polymyxin B Sulfate and Trimethoprim"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Polytrim"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"POLYMYXIN B SULFATE AND TRIMETHOPRIM SULFATE"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"POLYMYXIN B SULFATE and TRIMETHOPRIM SULFATE"},{"form":"SUSPENSION","route":"ORAL","productName":"SULFAMETHOXAZOLE and TRIMETHOPRIM"},{"form":"SUSPENSION","route":"ORAL","productName":"Sulfamethoxazole and Trimethoprim"},{"form":"SUSPENSION","route":"ORAL","productName":"sulfamethoxazole and trimethoprim"},{"form":"SUSPENSION","route":"ORAL","productName":"SULFATRIM"},{"form":"SUSPENSION","route":"ORAL","productName":"Sulfamethoxazole and Trimethoprim"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146103","MMSL":"3055","NDDF":"002873","UNII":"AN164J8Y0X","VUID":"4017735","CHEBI":"CHEBI:45924","VANDF":"4017735","INN_ID":"1047","RXNORM":"10829","UMLSCUI":"C0041041","chemblId":"CHEMBL1201080","ChEMBL_ID":"CHEMBL22","KEGG_DRUG":"D00145","DRUGBANK_ID":"DB00440","PDB_CHEM_ID":" TOP","PUBCHEM_CID":"5578","SNOMEDCT_US":"32792001","IUPHAR_LIGAND_ID":"10931","SECONDARY_CAS_RN":"56585-33-2","MESH_DESCRIPTOR_UI":"D014295"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Sun Pharmaceutical Industries, Inc","brandName":"Bactrim","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1973-","companyName":"Mutual Pharm","relationship":"Original Developer"},{"period":"present","companyName":"Dr Reddys Labs Sa","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"9.6 hours","clearance":"2.1 mL/min/kg","bioavailability":"98%","fractionUnbound":"0.5%","volumeOfDistribution":"1.5 L/kg"},"publicationCount":22765,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J01EA01","allCodes":["J01EA01","J01EE01","J01EE02","J01EE03","J01EE04","J01EE05","J01EE07","J04AM08"]},"biosimilarFilings":[],"originalDeveloper":"Mutual Pharm","recentPublications":[],"combinationProducts":[{"brandName":"Bactrim","ingredients":"sulfamethoxazole + trimethoprim"},{"brandName":"Bactrim DS","ingredients":"sulfamethoxazole + trimethoprim"},{"brandName":"Polytrim","ingredients":"Polymyxin B + trimethoprim"},{"brandName":"SULFATRIM","ingredients":"sulfamethoxazole + trimethoprim"},{"brandName":"Sulfamethoxazole and Trimethoprim","ingredients":"sulfamethoxazole + trimethoprim"}],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Novel Labs Inc","Novitium Pharma","Sun Pharm Industries","Teva","Watson Labs"],"status":"approved","companyName":"Dr Reddys Labs Sa","companyId":"dr-reddys-labs-sa","modality":"Small molecule","firstApprovalDate":"1973","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1973-07-30T00:00:00.000Z","mah":"MUTUAL PHARM","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-02-13T00:00:00.000Z","mah":"PHARM ASSOC","brand_name_local":null,"application_number":"NDA018615"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-09-03T00:00:00.000Z","mah":"CHARTWELL MOLECULAR","brand_name_local":null,"application_number":"ANDA077785"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-10-23T00:00:00.000Z","mah":"CHARTWELL MOLECULES","brand_name_local":null,"application_number":"ANDA078060"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-09-16T00:00:00.000Z","mah":"AMNEAL PHARMS NY","brand_name_local":null,"application_number":"ANDA076899"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-02-21T00:00:00.000Z","mah":"SOMERSET","brand_name_local":null,"application_number":"ANDA212231"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"598.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":10,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:10.858394+00:00","fieldsConflicting":5,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}